Abstract

Multiple studies have found the neutrophil to lymphocyte ratio (NLR) to be associated with adverse breast cancer (BC) prognosis and survival. Very limited data exist on the role of NLR and risk of BC. The BREOGAN study is a population-based case–control study conducted in Galicia, Spain. We examined the WBC- and NLR-BC relationships. The risk of BC increased with increasing levels of neutrophils percentage (NE%) (multivariable OR for the highest category (95% CI) = 2.14 (1.39–3.32), P-trend < 0.001) and of the NLR (multivariable OR for the highest category (95% CI) = 1.93 (1.26–2.97), P-trend < 0.001). Lymphocytes absolute (L#) and percentage (L%) were associated with a decreased risk of BC (multivariable OR for the highest category (95% CI) = 0.54 (0.35–0.83), and 0.51 (0.33–0.79), P-trend = 0.001 and < 0.001, respectively). The NLR-BC association was more pronounced among Luminal A BC (multivariable OR for the highest category (95% CI) = 2.00 (1.17–3.45), P-trend < 0.001), HER2-negative BC (multivariable OR for the highest category (95% CI) = 1.87 (1.16–3.02), P-trend < 0.001), and those with high total cholesterol and low H2O2 levels.

Details

Title
Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions
Author
Gago-Dominguez, Manuela 1 ; Matabuena Marcos 2 ; Redondo, Carmen M 3 ; Patel, Sandip Pravin 4   VIAFID ORCID Logo  ; Carracedo Angel 5 ; Ponte, Sara Miranda 2 ; Martínez, María Elena 6 ; Esteban, Castelao J 2 

1  Health Research Institute of Santiago (IDIS), Galician Public Foundation of Genomic Medicine (FPGMX), Genomic Medicine Group, International Cancer Genetics and Epidemiology Group, Santiago de Compostela, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897); University of California San Diego, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
2  Universidade de Santiago de Compostela, Centro de Investigación en Tecnoloxías da Información (CITIUS), Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000000109410645) 
3  Instituto de Investigación Sanitaria Galicia Sur, Oncology and Genetics Unit, Vigo, Spain (GRID:grid.11794.3a) 
4  University of California San Diego, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
5  Health Research Institute of Santiago (IDIS), Galician Public Foundation of Genomic Medicine (FPGMX), Genomic Medicine Group, International Cancer Genetics and Epidemiology Group, Santiago de Compostela, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897); Universidade de Santiago de Compostela, Forensic Department, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000000109410645) 
6  University of California San Diego, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California San Diego, Department of Family Medicine and Public Health, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41598-020-70077-z
ProQuest document ID
2430817713
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.